益方生物-U
(688382)
| 流通市值：44.09亿 | | | 总市值：63.62亿 |
| 流通股本：4.00亿 | | | 总股本：5.77亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 19,156,299.24 | 14,873,214.62 | 8,606,045.1 | 185,526,866.85 |
| 营业收入 | 19,156,299.24 | 14,873,214.62 | 8,606,045.1 | 185,526,866.85 |
| 二、营业总成本 | 327,620,052.49 | 224,987,384.25 | 91,335,787.52 | 469,863,109.82 |
| 营业成本 | 7,031,049.1 | 6,317,273.35 | 4,044,612.85 | - |
| 税金及附加 | 70,907.64 | 61,128.69 | 29,340.62 | 124,938.4 |
| 管理费用 | 43,184,858.85 | 24,297,341.62 | 10,644,755.92 | 60,851,853.54 |
| 研发费用 | 295,676,116.12 | 208,910,699.61 | 84,752,226.6 | 442,907,897.64 |
| 财务费用 | -18,342,879.22 | -14,599,059.02 | -8,135,148.47 | -34,021,579.76 |
| 其中:利息费用 | - | - | - | 182,889.52 |
| 其中:利息收入 | -19,712,098.72 | -14,199,271.32 | -8,058,138.58 | 33,894,350.9 |
| 加:公允价值变动收益 | 830,000 | 260,000 | - | - |
| 加:投资收益 | - | - | - | 6,559,881.5 |
| 信用减值损失(新) | -4,749,397.83 | -4,540,816.77 | -447,924.66 | -9,347,258.57 |
| 其他收益 | 7,076,641.36 | 176,641.36 | - | 3,148,345.43 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -305,306,509.72 | -214,218,345.04 | -83,177,667.08 | -283,975,274.61 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -305,306,509.72 | -214,218,345.04 | -83,177,667.08 | -283,975,274.61 |
| 六、净利润 | -305,306,509.72 | -214,218,345.04 | -83,177,667.08 | -283,975,274.61 |
| 持续经营净利润 | -305,306,509.72 | -214,218,345.04 | -83,177,667.08 | -283,975,274.61 |
| 归属于母公司股东的净利润 | -305,306,509.72 | -214,218,345.04 | -83,177,667.08 | -283,975,274.61 |
| (一)基本每股收益 | -0.53 | -0.37 | -0.14 | -0.49 |
| (二)稀释每股收益 | -0.53 | -0.37 | -0.14 | -0.49 |
| 八、其他综合收益 | -1,629,834.88 | -984,499.95 | -593,516.15 | -337,857.53 |
| 归属于母公司股东的其他综合收益 | -1,629,834.88 | -984,499.95 | -593,516.15 | -337,857.53 |
| 九、综合收益总额 | -306,936,344.6 | -215,202,844.99 | -83,771,183.23 | -284,313,132.14 |
| 归属于母公司股东的综合收益总额 | -306,936,344.6 | -215,202,844.99 | -83,771,183.23 | -284,313,132.14 |
| 公告日期 | 2024-10-30 | 2024-08-23 | 2024-04-30 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |